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This study investigated the effects of the new aldose reductase inhibitor benzofuroxane derivative 5(6)-(benzo[𝑑]thiazol-2-
ylmethoxy)benzofuroxane (BF-5m) on the prolongation of cardiac QT interval and increase of coronary perfusion pressure (CPP)
in isolated, high glucose (33.3mMD-glucose) perfused rat hearts. BF-5mwas dissolved in theKrebs solution at a final concentration
of 0.01 𝜇M, 0.05 𝜇M, and 0.1 𝜇M. 33.3mM D-glucose caused a prolongation of the QT interval and increase of CPP up to values of
190 ± 12ms and 110 ± 8mmHg with respect to the values of hearts perfused with standard Krebs solution (11.1mMD-glucose). The
QT prolongation was reduced by 10%, 32%, and 41%, respectively, for the concentration of BF-5m 0.01𝜇M, 0.05 𝜇M, and 0.1 𝜇M.
Similarly, the CPPwas reduced by 20% for BF-5m 0.05 𝜇Mand by 32% for BF-5m 0.1 𝜇M.BF-5m also increased the expression levels
of sirtuin 1,MnSOD, eNOS, andFOXO-1, into the heart.Thebeneficial actions of BF-5mwere partly abolished by the pretreatment of
the ratswith the inhibitor of the sirtuin 1 activity EX527 (10mg/kg/day/7 days i.p.) prior to perfusion of the heartswith high glucose +
BF-5m (0.1 𝜇M).Therefore, BF-5m supplies cardioprotection from the high glucose induced QT prolongation and increase of CPP.
1. Introduction
Hyperglycemia during the diabetes has detrimental effects
on various organs including eye, kidney, central nervous
system, and heart [1]. Hyperglycemia favors the insurgence
of coronary artery disease, peripheral arterial diseases, car-
diomyopathy, angina, and myocardial infarction [1]. Among
these, the most dangerous consequence of the hyperglycemia
is the prolongation of the cardiac QT interval, which leads
diabetic patients to sudden death [2]. Long cardiac QT inter-
val is partly sensitive to antioxidant drugs acting on the nitric
oxide bioavailability, glycosylated products, accumulation of
reactive oxygen species, and impairment of ionic pumps
in models of isolated high glucose perfused heart [3, 4].
Increased interest, therefore, has gained the discovery of new
drugs that may modulate pathways involved in glucose
metabolism and hyperglycemia-induced modifications, in
order to produce cardiovascular protection. In this context,
one pathway that could be targeted is the aldose reductase
(ALR2), because it contributes to the deleterious actions of
hyperglycemia onto the cardiovascular system by inducing
oxidative damage into the heart following diabetes [5–9].
Recently, Sartini et al. [10] discovered a series of new ben-
zofuroxane derivatives which inhibits the aldose reductase
(ALR2). These compounds spontaneously release NO, pos-
sess a hydroxyl radical scavenging activity, and account for
multieffective agents for the treatment of cardiovascular dia-
betic complications. For this, the first aim of the study was
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to investigate the effects of the BF-5m, on the prolongation
of cardiac QT interval and increase of the CPP induced by
perfusion with high glucose of isolated rat heart.
In addition, since the action of ALR2 on glucose meta-
bolism is linked to depletion into the cells of the cofactor
NAD+ [11] and SIRT1 is a NAD1-dependent protein deace-
tylase which belongs to a class of proteins that lead to
improved energy consumption, limitation of oxidative stress,
and reduced DNA damage [12, 13], the second aim of the
study was to investigate whether there is an involvement
of the sirtuin 1 (SIRT1) in the cardiac effects of BF-5m.
SIRT1 is one of the better characterized sirtuins with multiple
protective actions in many pathological conditions, through
involvement of several molecular pathways, deacetylation
of mediators of oxidative stress, inflammation, apoptosis,
and transcription factors, and plays an important role in
the regulation of glucose consumption by regulating insulin
expression in vivo [14, 15]. SIRT1 also has strong antioxidant
action [16].
2. Material and Methods
2.1. Drug. BF-5m, 5(6)-(benzo[𝑑]thiazol-2-ylmethoxy)ben-
zofuroxane, was synthesized at the Department of Phar-
macy of the University of Pisa, Italy, following a previously
reported procedure [10]. Briefly, alkylation of the commer-
cially available 4-amino-3-nitrophenol with chloroacetoni-
trile, in the presence of anhydrous potassium carbonate,
provided the 2-(4-amino-3-nitrophenoxy)acetonitrile which,
through reaction with o-aminothiophenol, gave the key
intermediate 4-[(benzo[𝑑]thiazol-2-yl)methoxy]-2-nitrobe-
nzenamine. Treatment with sodium nitrite in concentrated
hydrochloric acid and then with sodium azide in water gave
the corresponding azido-derivative, which cyclized to the
target inhibitor, 5(6)-(benzo[𝑑]thiazol-2-ylmethoxy)benzo-
furoxane, when heated under reflux in acetic acid.
2.2. Isolated Heart Preparation. Male Sprague-Dawley rats
(3-4 months old, with a weight of 210 ± 20 g) were anaesthe-
tised with urethane (1.2mg/kg i.p.) and heparinized (sodium
heparin, 250 IU, i.p. 10min before heart removal). Subse-
quently, the hearts were quickly excised and placed in ice-
cold Krebs solution (composition in mmol/L: 11.1 D(+)-
glucose; 1.4 CaCl
2
; 118.5 NaCl; 25.0 NaHCO
3
; 1.2 MgSO
4
;
1.2 NaH
2
PO
4
; 4.0 KCl). Then, the hearts were connected
to a Langendorff apparatus via the aorta and retrogradely
perfused at 37∘C under constant flow (9-10mL/min) with the
Krebs solution bubbled with 95% O
2
-5% CO
2
and composed
as described above.
A total of 82 hearts were used. Of these, 12 were excluded
having a sinus rate of <210 beats per minute or a coronary
perfusion pressure (CPP) <60mmHg between 5 and 15min
after beginning of the perfusion; hearts not in sinus rhythm
during the study were also excluded.The remaining 70 hearts
having a sinus rate of >210 beats per minute or CPP >
60mmHg, between 5 and 15min after beginning, were used
in the study and divided into the following experimental
groups (𝑛 = 10 rats for each group): (i) control: hearts per-
fused for 2 hours with a Krebs solution containing D-glucose
at 11.1mM [4, 5]; (ii) high glu: hearts perfused for 2 hours
with Krebs solution containing D-glucose at 33.3mM [4, 5];
(iii) high glu + DMSO: hearts perfused with Krebs solution
containing 1%DMSO+D-glucose at 33.3mM; (iv) high glu +
BF-5m: hearts perfused for 2 hours with Krebs solution
containing D-glucose at 33.3mM + BF-5m (0.01𝜇M in 1%
DMSO); (v) high glu + BF-5m: hearts perfused for 2 hours
with Krebs solution containing D-glucose at 33.3mM + BF-
5m (0.05𝜇M, in 1% DMSO); (vi) high glu + BF-5m: hearts
perfused for two hours withKrebs solution containingD-glu-
cose at 33.3mM + BF-5m (0.1 𝜇M, in 1% DMSO). Moreover,
in order to assess the role of SIRT1 in theBF-5mcardiac effects
additional studies were done on 10 hearts excised from rats
pretreated for 7 days (10mg/kg/day i.p.) [17] with EX527 and
perfused with a Krebs solution with high glucose + BF-5m
0.1 𝜇M. In these theQT interval, CPP values, and biochemical
parameters mentioned below were monitored.
2.3. QT Interval and CPP Measurements. QT interval, for
each heart, was recorded by a unipolar ECG with a stainless
steel wire electrode in the apex of left ventricularmusclemass,
with a second electrode connected to the aorta.This electrode
arrangement gave clear P waves and ventricular complexes.
An ECG (chart speed 50mm/s) was recorded for 4min every
10min for 2 h. The ECG was analysed and heart rate (RR
interval) and the width of the ventricular complex (QT) at
100% repolarization (QT100) were measured.The CPP in the
aortic line was monitored using a Statham Spectramed pres-
sure transducer connected to a chart recorder (Grass, 79E,
Quincy,MA,USA). Temperature wasmaintained constant by
means of a heated (37∘C)water jacket.On establishing a stable
value (20–30min following cannulation) CPP was calculated
according to Di Filippo et al. [4]. Briefly, CPP value was
expressed either as themean of each 10-min value throughout
the entire experiment or as the mean of the steady-state
increment above baseline when an increase of CPP was
evident during an experiment. All experimental procedures
were approved by Animal Care Ethical Committee of the
Naples University in accordance with Italian (Decree 116/92)
and European Community (E.C. L358/1 18/12/86) guidelines
on the use and protection of laboratory animals.
2.4. Hematoxylin and Eosin Staining. At the end of the per-
fusion period the hearts were cut into two halves and one was
immediately frozen in liquid nitrogen and stored at −80∘C.
Thehematoxylin and eosin stainingwas conducted according
to Marfella et al. [18] protocol and 200x magnification
pictures were taken.
2.5. Western Blot Analysis and SIRT1 Activity Assay. Western
blotting analysis was performed from the homogenized
frozen biopsy according to Di Filippo et al. [19]. We used
(i) primary anti-SIRT1 antibody (1 : 1000, Abcam, Cambridge,
UK), (ii) specific monoclonal antibody directed against
FOXO-1 (1 : 500, Millipore, California, USA), (iii) anti-
MnSOD primary antibody (1 : 800, Millipore, California,
USA), (iv) anti-𝛽-actinmonoclonal antibody (1 : 1000, Sigma-
Aldrich), and (v) anti-eNOS sc-654 (1 : 500, Santa Cruz Bio-
tech, USA) with an enhanced chemiluminescence detection
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reagent (ECL), quantified by densitometry using a BioRad
ChemiDoc MP Imaging system. The following secondary
antibodies were used: goat anti-mouse (1 : 1000, Santa Cruz
Biotech, USA) and goat anti-rabbit (1 : 1000, Santa Cruz Bio-
tech, USA). The deacetylase activity of SIRT1 was measured
by means of a commercial fluorometric kit (Abcam, Cam-
bridge, UK) and normalized by protein content.
2.6. Sorbitol Assay in Heart Samples. A procedure early
described in literature [20] with slightmodificationswas used
to assess the sorbitol levels in the heart homogenates by
fluorimetry. Briefly, one mL of the supernatants was incu-
bated for 5min at 37∘C in presence of 50 𝜇mol glycine buffer,
2 𝜇mol magnesium chloride, and 0.2 𝜇mol nicotinamide
adenine dinucleotide (NAD) and reaction initiated by the
addition of 0.6U of sorbitol dehydrogenase. A standard curve
was constructed with sorbitol from 0.4 to 10 𝜇g/mL; the
fluorescence fromNADH formationwasmeasured at 450 nm
and expressed as sorbitol 𝜇g/mL.
2.7. RNA Isolation and Quantification. Total RNA was
extracted from the heart tissue (∼50mg) using the Rneasy
Plus Mini Kit (Qiagen) according the manufacturer’s pro-
tocol from Animal Cells. Then RNA was quantified using
NanoDrop 2000c Spectrophotometer (Thermo Scientific,
Waltham, MA, USA) according to Rossi et al. [21].
2.8. RNA Retrotranscription and Real Time PCR Reaction.
cDNA synthesis was obtained using SuperScript III Reverse
Transcriptase Kit (Invitrogen, USA) starting from 1.5 𝜇g of
total RNA. In the subsequent q-PCR reaction performedwith
Power SYBR Green PCR Master Mix (Applied Biosystems,
UK), SIRT1 mRNA has been quantified and normalized
using 𝛽-actin as housekeeping gene in CFX96 Real Time
System (BioRad) cycler (BioRad Laboratories, Inc.). Primers
sequences were as follows: 5󸀠-TGTTTCCTGTGGGATACC-
TGA-3󸀠 (sense) and 5󸀠-TGAAGAATGGTCTTGGGTCTTT-
3󸀠 (antisense) for SIRT1 and 5󸀠-CGAGTACAACCTTCT-
TGCAG-3󸀠 (sense) and 5󸀠-TTCTGACCCATACCCACCAT-
3󸀠 (antisense) for 𝛽-actin. Relative quantification of gene
expression was normalized to beta-actin using the 2−ΔΔCt
method [19, 21].
2.9. Statistical Analysis. Data are expressed as means ± stan-
dard error of the mean (s.e.m.). Student’s 𝑡-test (when only
two groups were compared) or one-way ANOVA followed
by Dunnett’s test (more than two experimental groups) was
used. 𝑃 < 0.05 was considered statistically significant.
3. Results
Figure 1 shows representative pictures of the heart structure
derangement caused by perfusion of the hearts with the a
Krebs solution containing high glucose concentration (D-
glucose, 33.3mM) with respect to the hearts perfused with
a Krebs solution containing normal glucose concentration
(D-glucose, 11.1M), in presence or absence of the first active
dose of the compound BF-5m (e.g., 0.05 𝜇M). There was
clear evidence of a damaged structure with no or few signs
of well tissue organization (e.g., bands, Z line) following
high glucose perfusion. In contrast, a discrete preservation
of the heart structure was seen in rat hearts perfused with
high glucose + BF-5m with an almost intact structure of
the tissue. This cardiac preservation disappeared when the
rats were pretreated with the SIRT1 activity inhibitor EX527
(10mg/kg/day/7 days i.p.) and then perfused with high
glucose + BF-5m 0.1 𝜇M (Figure 1).
3.1. BF-5mDecreased QT Interval and CPP in Rats Hearts Per-
fused with the High Glucose Concentration. 11.1mM glucose
(control) exhibited a QT interval of 112 ± 5ms and a CPP of
70 ± 3mmHg.These values were increased up to 190 ± 12ms
(𝑃 < 0.01 versus control) for QT and up to 110 ± 8mmHg
(𝑃 < 0.01 versus control) for CPP in the heart perfused with
glucose 33.3mM. The addition of BF-5m (0.01 𝜇M; 0.05 𝜇M;
0.1 𝜇M) to Krebs solution containing a high glucose concen-
tration diminished the QT interval of 10%, 32%, and 41%
with calculated values of 170 ± 14ms, 130 ± 12ms, and
113 ± 20ms, respectively. Similarly, the CPP was reduced by
3% (107±12mmHg), 20% (88±5mmHg), and 32% by BF-5m
(Figure 2). Pretreatment (7 days) of the rats with EX527 prior
to the perfusion of the hearts with high glu + BF-5m 0.1 𝜇M
decreased the BF-5m cardioprotection by reporting the QT
interval at 174 ± 11ms (𝑃 < 0.01) and CCP at 102 ± 7mmHg
(𝑃 < 0.01 versus high glu + BF-5m 0.1 𝜇M) (Figure 2).
3.2. Effects of BF-5m on SIRT1 Levels and Activity in
Rats Hearts Perfused with the High Glucose Concentration.
Figure 3 showed that SIRT1 gene and protein expression
significantly decreased in rat hearts perfused for two hours
with Krebs solution containing a high glucose concentration
(𝑃 < 0.01 versus control). Addition of BF-5m at 0.01, 0.05,
and 0.1 𝜇M to the Krebs solution plus glucose at 33.3mM sig-
nificantly increased the cardiac SIRT1 gene expression (e.g.,
+65%, +160%, and +227%) and protein levels (e.g., +50%,
+105%, and +160%; Figure 3). SIRT1 deacetylase activity was
significantly increased in heart homogenates from high glu +
BF-5m with respect to the activity measured in hearts from
high glu.The SIRT1 deacetylase activity was 450±32 RFU/𝜇g
of protein in high glu perfused hearts; 492 ± 48 RFU/𝜇g of
protein in high glu + BF-5m 0.01 𝜇M; 726 ± 64 RFU/𝜇g of
protein in high glu + BF-5m 0.51𝜇M; 1149 ± 86 RFU/𝜇g of
protein in high glu + BF-5m 0.1 𝜇M.
EX527 pretreatment (10mg/kg/day/7 days i.p.) did not
affect SIRT1 gene and protein expression levels but dimin-
ished (−57%) the BF-5m cardioprotection (Figures 1 and 2).
3.3. Effects of BF-5m onMnSOD, eNOS Expression, and Tissue
Sorbitol Content. As shown in Figures 4(a)–4(c), the per-
fusion of the hearts with high glu + BF-5m (0.01𝜇M; 0.05 𝜇M;
0.1 𝜇M) increased the levels of MnSOD and eNOS compared
to the hearts perfused with the high glucose only. In contrast,
the effects of 0.1 𝜇M BF-5m on MnSOD and eNOS were
decreased by the EX527 pretreatment (Figures 4(a)–4(c)).
The tissue sorbitol content as marker of the aldose reductase
activity was increased in heart perfused with high glu with
respect to the content of vehicle. This increase was not
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(a) (b)
(c) (d)
Figure 1: Representative pictures from hematoxylin and eosin staining of cardiac tissue. Rat hearts were perfused with Krebs solution
containing (a) D-glucose 11.1mM (control); (b) glucose 33.3mM (high glu); (c) high glu + BF-5m (0.1 𝜇M); (d) high glu + BF-5m (0.1 𝜇M) +
EX527 (10mg/kg/day i.p.). 200x magnification; scale bar = 100 𝜇m.
C
on
tro
l
0.
01
H
ig
h 
gl
u 
+
D
M
SO
 1
% 0.
1
EX527
#
∘∘
∘∘
∗∗
∗∗∘
High glu +
BF-5m
High glu + BF-5m
(𝜇M) +
(𝜇M)
0
50
100
150
200
250
Q
T 
in
te
rv
al
 (m
s±
s.e
.)
H
ig
h 
gl
u
0.
05 0.
1
(a)
C
or
on
ar
y 
pe
rf
us
io
n 
pr
es
su
re #
∘∘∘∘
∗∗
∗∘
0
25
50
75
100
125
(m
m
H
g
±
s.e
.)
C
on
tro
l
0.
01
H
ig
h 
gl
u 
+
D
M
SO
 1
% 0.
1
EX527
High glu +
BF-5m
High glu + BF-5m
(𝜇M) +
(𝜇M)
H
ig
h 
gl
u
0.
05 0.
1
(b)
Figure 2: (a) Cardiac QT interval in hearts of Sprague-Dawley rats perfused for two hours in a Langendorff apparatus with Krebs solution
containing D-glucose 11.1mM (control); glucose 11.1mM + DMSO 1% (vehicle); glucose 33.3mM (high glu); high glu + BF-5m (0.01, 0.05,
and 0.1 𝜇M); high glu + BF-5m (0.1 𝜇M) + EX527 (10mg/kg/day i.p.). (b) Coronary perfusion pressure (CPP) recorded on a Power Lab system
following exposure of perfused hearts to the same treatments as in panel (a). Values are expressed as the mean of 10 observations ± s.e.m.
Significant differences versus control are reported as ∘𝑃 < 0.05 and ∘∘𝑃 < 0.01; significant differences versus high glu are reported as ∗𝑃 < 0.05
and ∗∗𝑃 < 0.01; significant differences versus high glu + BF-5m 0.1 𝜇M are reported as #𝑃 < 0.01.
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Figure 3: (a) SIRT1 in perfused hearts following treatment with D-glucose 11.1mM (control); glucose 11.1mM +DMSO 1% (vehicle); glucose
33.3mM (high glu); high glu + BF-5m (0.01, 0.05, and 0.1𝜇M); high glu + BF-5m (0.1 𝜇M) + EX527 (10mg/kg/day i.p.). Total RNA was
extracted from the hearts and reverse transcribed into cDNA using superscript reverse transcriptase system. The expression of SIRT1 was
quantified by qPCR using commercially available rat primers. Results are expressed as arbitrary units based on calculation of 2−ΔΔCt method.
∘
𝑃 < 0.01 versus control; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus high glu. (b) Addition of BF-5m (0.01, 0.05, and 0.1 𝜇M) to the high glucose
Krebs solution dose-dependently increased the expression of SIRT1. Results are derived from western blotting (panel (c) representative) and
expressed as densitometric units (mean ± s.e.m. of 𝑛 = 10 observations for each group). Significant differences versus control are reported as
∘
𝑃 < 0.05 and ∘∘𝑃 < 0.01; significant differences versus high glu are reported as ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01; significant differences versus high
glu + BF-5m 0.1 𝜇M are reported as ∘𝑃 < 0.01.
observed after the treatment of the rats with the BF-5m at all
the concentration used (Figure 4(d)).
3.4. Effect of BF-5m on FOXO-1. BF-5m modified the levels
of cardiac FOXO-1 (Forkhead transcription factor 1), which
is a direct target of SIRT1. Western blotting analysis showed
lower expression of this protein in hearts perfused with
high glucose solution. This was reported towards the control
values by high glu + BF-5m (Figure 5).The inhibitor of SIRT1
activity EX527 also inhibited the restoring of FOXO-1 levels
operated by the BF-5m (Figure 5).
4. Discussion
Here we show that inhibition of the endogenous enzyme
aldose reductase (ALR2) activity by the newly synthetized ben-
zofuroxane derivative 5(6)-(benzo[𝑑]thiazol-2-ylmethoxy)ben-
zofuroxane (BF-5m) results in cardioprotection from the
electrical instability and increased vasomotor tone caused by
high levels of glucose into the heart. This cardioprotection is
characterized by reduction of the long cardiac QT interval
and the decrease of the coronary perfusion pressure (CPP).
The ALR2 is a critical enzyme when there is a high glucose
condition into cells and tissues since this by catalyzing the
reduction of glucose to sorbitol [22] favors accumulation of
this polyol into the cell cytoplasm of organs and tissues and
determines local generation of reactive oxygen species and
damage [22]. Over the years many compounds have shown
potent inhibitory effects against the enzyme aldose reductase
(ALR2) including, for example, epalrestat, fidarestat, lidore-
stat, and sorbinil [22–24]. However, some of these were with-
drawn from clinical trials because they showed undesirable
effects such as skin reactions or liver toxicity [25]. Numerous
efforts have been made, therefore, to identify molecules that
could effectively block the activity of ALR2, limit the negative
effects fromprolonged exposure to high glucose, and possibly
have few or no side effects. Among these, Sartini et al. [10]
proposed a novel class of nonhydantoin noncarboxylic acid
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Figure 4: (a) MnSOD expression in hearts perfused with glucose 11.1mM (control); glucose 11.1mM +DMSO 1% (vehicle); glucose 33.3mM
(high glu); high glu + BF-5m (0.01, 0.05, and 0.1 𝜇M); high glu + BF-5m (0.1 𝜇M) + EX527 (10mg/kg/day i.p.). (b) eNOS expression levels in
hearts perfused as in panel (a). Results are derived from western blotting (panel (c) representative) and expressed as densitometric units; (d)
tissue sorbitol content (𝜇g/mL). Mean ± s.e.m. of 𝑛 = 10 observations for each group. Significant differences versus control are reported as
∘
𝑃 < 0.05 and ∘∘𝑃 < 0.01; significant differences versus high glu are reported as ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01; significant differences versus high
glu + BF-5m 0.1 𝜇M are reported as #𝑃 < 0.01.
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Figure 5: (a) Expression of FOXO-1 in hearts perfusedwith glucose 11.1 mM(control); glucose 11.1mM+DMSO 1% (vehicle); glucose 33.3mM
(high glu); high glu + BF-5m (0.01, 0.05, and 0.1 𝜇M); high glu + BF-5m (0.1 𝜇M)+EX527 (10mg/kg/day i.p.). Results are derived fromwestern
blotting (panel (b) representative) and expressed as densitometric units and represented the mean ± s.e.m. of 𝑛 = 10 observations for each
group. Significant differences versus control are reported as ∘𝑃 < 0.05 and ∘∘𝑃 < 0.01; significant differences versus high glu are reported as
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01; significant differences versus high glu + BF-5m 0.1 𝜇M are reported as #𝑃 < 0.01.
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inhibitors, featuring the benzofuroxane core [22, 26] as new
scaffold interacting with the so-called ALR2 anion site.
Merging submicromolar ALR2 inhibitory activities with sig-
nificant ROS scavenging properties, these compounds have
been identified as the ideal therapeutic treatment for the high
glucose-related pathologies [10] as could be the alterations
of cardiac electrical stability. Effectively, BF-5m reduced the
prolongation of cardiac QT interval, sensitive marker of
electrical instability, in our setting.
BF-5m also promotes increase of the expression and
activity of endogenous antioxidant pathways and free radical
scavengers such as SIRT1 andMnSOD, its downstream target
[27], into the heart following exposure to a high glucose
stimulus. Indeed, the high glucose to the heart caused
decrease of the protein SIRT1 into the tissue, an effect that
was reverted by theBF-5m. SIRT1 isNAD1-dependent protein
deacetylase which belongs to a class of proteins that lead
to improved energy consumption, limitation of oxidative
stress, and reduced DNA damage [12, 13]. SIRT1, through
involvement of several molecular pathways and deacetylation
of mediators of oxidative stress, inflammation, apoptosis, and
transcription factors, possesses multiple protective actions in
many pathological conditions. SIRT1 also plays an important
role in the regulation of insulin expression by glucose con-
centration [14, 15]. So, back to our game, BF-5m was able
to reduce the structural and functional cardiac derangement
caused by high glucose into the myocardium through the
modulation of SIRT1 activity. This result is also confirmed by
the reduction in the expression of the Forkhead transcription
factor 1 (FOXO-1), the direct downstream product of SIRT1
activity into tissues. FOXO-1 is a transcription factor that is
regulated by SIRT1 through its deacetylase activity [28, 29]
and it regulates gluconeogenesis, glycogenolysis, and adipo-
genesis [30]. From the clinical point of view, upregulated
FOXO-1 raises a state of insulin resistance anddiabetes, due to
a loss of insulin sensitivity, and the consequent hyperglycemia
or high glucose accelerates cellular damage [31]. In our case,
a condition of diminished activity of FOXO-1 caused by high
glucose may be one of the actors accounting for an altered
homeostasis at cardiac levels which may have led to reduced
perfusion of heart and finally electrical instability.
5. Conclusions
These results suggest that the new aldose reductase inhibitor
benzofuroxane derivative BF-5m supplies cardioprotection
from the high glucose induced QT prolongation and increase
of CPP. The mechanism of action involves the increase of
SIRT1 protein and activity into the heart tissue, together
with the modulation of the expression and activity of its
downstream mediators MnSOD and FOXO-1.
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